Selectivity data: assessment, predictions, concordance, and implications.
暂无分享,去创建一个
Ian A. Watson | M. Vieth | P. Iversen | Suntara Cahya | Cen Gao | D. Cummins | Ji-Bo Wang | C. Nicolaou
[1] Michal Vieth,et al. What general conclusions can we draw from kinase profiling data sets? , 2013, Biochimica et biophysica acta.
[2] Maria F. Sassano,et al. Automated design of ligands to polypharmacological profiles , 2012, Nature.
[3] Eric J. Martin,et al. Profile-QSAR and Surrogate AutoShim Protein-Family Modeling of Proteases , 2012, J. Chem. Inf. Model..
[4] Michael J. Keiser,et al. Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.
[5] Robert P. Sheridan,et al. Three Useful Dimensions for Domain Applicability in QSAR Models Using Random Forest , 2012, J. Chem. Inf. Model..
[6] Mindy I. Davis,et al. Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.
[7] George Karypis,et al. Improved machine learning models for predicting selective compounds , 2011, BCB '11.
[8] Eric J. Martin,et al. Profile-QSAR: A Novel meta-QSAR Method that Combines Activities across the Kinase Family To Accurately Predict Affinity, Selectivity, and Cellular Activity , 2011, J. Chem. Inf. Model..
[9] P. Hajduk,et al. Navigating the kinome. , 2011, Nature chemical biology.
[10] Michal Vieth,et al. Structure-guided expansion of kinase fragment libraries driven by support vector machine models. , 2010, Biochimica et biophysica acta.
[11] Stephen V Frye,et al. The art of the chemical probe. , 2010, Nature chemical biology.
[12] Ian A. Watson,et al. Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches. , 2009, Journal of medicinal chemistry.
[13] Gavin Harper,et al. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. , 2008, Journal of medicinal chemistry.
[14] Ian A. Watson,et al. Chemical fragments as foundations for understanding target space and activity prediction. , 2008, Journal of medicinal chemistry.
[15] Jean-Pierre Doucet,et al. Nonlinear SVM Approaches to QSPR/QSAR Studies and Drug Design , 2007 .
[16] Michael L. Creech,et al. Integration of biological networks and gene expression data using Cytoscape , 2007, Nature Protocols.
[17] P. Clemons,et al. Chemogenomic data analysis: prediction of small-molecule targets and the advent of biological fingerprint. , 2007, Combinatorial chemistry & high throughput screening.
[18] Andreas Bender,et al. "Bayes Affinity Fingerprints" Improve Retrieval Rates in Virtual Screening and Define Orthogonal Bioactivity Space: When Are Multitarget Drugs a Feasible Concept? , 2006, J. Chem. Inf. Model..
[19] G. V. Paolini,et al. Global mapping of pharmacological space , 2006, Nature Biotechnology.
[20] Kim E. Garbison,et al. The Minimum Significant Ratio: A Statistical Parameter to Characterize the Reproducibility of Potency Estimates from Concentration-Response Assays and Estimation by Replicate-Experiment Studies , 2006, Journal of biomolecular screening.
[21] M. Vieth,et al. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. , 2004, Biochimica et biophysica acta.
[22] Dragos Horvath,et al. Predicting ADME properties and side effects: the BioPrint approach. , 2003, Current opinion in drug discovery & development.
[23] T. Hunter,et al. The Protein Kinase Complement of the Human Genome , 2002, Science.
[24] Thorsten Joachims,et al. Making large-scale support vector machine learning practical , 1999 .
[25] J. H. Ward. Hierarchical Grouping to Optimize an Objective Function , 1963 .